JP2008524218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008524218A5 JP2008524218A5 JP2007546709A JP2007546709A JP2008524218A5 JP 2008524218 A5 JP2008524218 A5 JP 2008524218A5 JP 2007546709 A JP2007546709 A JP 2007546709A JP 2007546709 A JP2007546709 A JP 2007546709A JP 2008524218 A5 JP2008524218 A5 JP 2008524218A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- compound
- hodgkin lymphoma
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 5
- -1 1- (2,2-difluoro-2-deoxy-β-D-ribofuranosyl) -4- (2-propyl-1-oxopentyl) aminopyrimidin-2-one p-toluenesulfonic acid Chemical compound 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- ZFXJGSZRYYQNBZ-MQRVLJRQSA-N O.CC1=CC=C(C=C1)S(=O)(=O)O.FC1([C@@H](O[C@@H]([C@H]1O)CO)N1C(N=C(C(=C1)N)C(C(CCC)CCC)=O)=O)F Chemical compound O.CC1=CC=C(C=C1)S(=O)(=O)O.FC1([C@@H](O[C@@H]([C@H]1O)CO)N1C(N=C(C(=C1)N)C(C(CCC)CCC)=O)=O)F ZFXJGSZRYYQNBZ-MQRVLJRQSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63742204P | 2004-12-17 | 2004-12-17 | |
| US60/637,422 | 2004-12-17 | ||
| PCT/US2005/043125 WO2006065525A1 (en) | 2004-12-17 | 2005-11-30 | Amide prodrug of gemcitabine, compositions and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008524218A JP2008524218A (ja) | 2008-07-10 |
| JP2008524218A5 true JP2008524218A5 (enExample) | 2012-03-08 |
| JP5022911B2 JP5022911B2 (ja) | 2012-09-12 |
Family
ID=36168678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007546709A Expired - Fee Related JP5022911B2 (ja) | 2004-12-17 | 2005-11-30 | ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US7691827B2 (enExample) |
| EP (1) | EP1831237B1 (enExample) |
| JP (1) | JP5022911B2 (enExample) |
| KR (1) | KR100874052B1 (enExample) |
| CN (1) | CN101080417B (enExample) |
| AR (1) | AR055009A1 (enExample) |
| AT (1) | ATE405573T1 (enExample) |
| AU (1) | AU2005316922B2 (enExample) |
| BR (1) | BRPI0519117A2 (enExample) |
| CA (1) | CA2589850C (enExample) |
| CY (1) | CY1108447T1 (enExample) |
| DE (1) | DE602005009255D1 (enExample) |
| DK (1) | DK1831237T3 (enExample) |
| EA (1) | EA011868B1 (enExample) |
| ES (1) | ES2310860T3 (enExample) |
| HR (1) | HRP20080529T3 (enExample) |
| IL (1) | IL183666A (enExample) |
| MA (1) | MA29154B1 (enExample) |
| MX (1) | MX2007007228A (enExample) |
| MY (1) | MY143677A (enExample) |
| NO (1) | NO20073368L (enExample) |
| NZ (1) | NZ554732A (enExample) |
| PE (1) | PE20060771A1 (enExample) |
| PL (1) | PL1831237T3 (enExample) |
| PT (1) | PT1831237E (enExample) |
| RS (1) | RS50629B (enExample) |
| SI (1) | SI1831237T1 (enExample) |
| TW (1) | TWI326687B (enExample) |
| UA (1) | UA86119C2 (enExample) |
| WO (1) | WO2006065525A1 (enExample) |
| ZA (1) | ZA200705019B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652633C (en) * | 2006-06-21 | 2014-03-25 | Eli Lilly And Company | Crystalline forms of gemcitabine amide prodrug, compositions and use thereof |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| CN101525361B (zh) * | 2009-04-21 | 2010-11-17 | 济南圣鲁金药物技术开发有限公司 | 基于吉西他滨结构的前药及其合成方法及应用 |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CN102432654A (zh) * | 2011-09-26 | 2012-05-02 | 宋云龙 | 吉西他滨酰胺衍生物及其制备方法和用途 |
| CA2890359A1 (en) | 2012-11-07 | 2014-05-15 | Zucai SUO | Substituted gemcitabine aryl amide analogs and treatment methods using same |
| KR20150082606A (ko) | 2012-11-13 | 2015-07-15 | 보옌 테라퓨틱스, 인크. | 겜시타빈 전구약물 및 그의 용도 |
| US10059733B2 (en) | 2014-03-03 | 2018-08-28 | Nucorion Pharmaceuticals, Inc. | Gemcitabine analogs |
| WO2016078160A1 (zh) * | 2014-11-17 | 2016-05-26 | 常州方圆制药有限公司 | 胞苷衍生物及其应用 |
| US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
| AU2019207626B2 (en) | 2018-01-10 | 2023-10-05 | Nucorion Pharmaceuticals, Inc. | Phosphor(n)amidatacetal and phosph(on)atalcetal compounds |
| US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
| AU2019216531A1 (en) | 2018-02-02 | 2020-09-24 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| CN113166189A (zh) * | 2018-04-26 | 2021-07-23 | 纳米医学控股有限公司 | 吉西他滨两亲性前体药物 |
| CN108864250A (zh) * | 2018-05-29 | 2018-11-23 | 北京大学 | 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用 |
| KR20210057025A (ko) * | 2018-08-03 | 2021-05-20 | 셀릭스 바이오 프라이빗 리미티드 | 암의 치료를 위한 조성물 및 방법 |
| MX2022000573A (es) | 2019-07-17 | 2022-02-10 | Nucorion Pharmaceuticals Inc | Compuestos ciclicos de desoxirribonucleotido. |
| CN115605492B (zh) | 2020-04-21 | 2025-09-16 | 配体制药股份有限公司 | 核苷酸前药化合物 |
| PL442924A1 (pl) * | 2022-11-23 | 2024-05-27 | Politechnika Śląska | Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| YU43193A (sh) * | 1992-06-22 | 1997-01-08 | Eli Lilly And Company | 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi |
| RU2131880C1 (ru) * | 1992-06-22 | 1999-06-20 | Эли Лилли Энд Компани | Способ получения обогащенных бета-аномером нуклеозидов |
| GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
| ATE236188T1 (de) * | 1997-01-24 | 2003-04-15 | Conpharma As | Gemcitabin-derivate |
| US6624142B2 (en) * | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
| US6376470B1 (en) * | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
| WO2004041203A2 (en) * | 2002-11-04 | 2004-05-21 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| US7846436B2 (en) * | 2003-11-28 | 2010-12-07 | Chemgenes Corporation | Oligonucleotides and related compounds |
-
2005
- 2005-11-30 US US11/719,705 patent/US7691827B2/en not_active Expired - Fee Related
- 2005-11-30 BR BRPI0519117-3A patent/BRPI0519117A2/pt not_active IP Right Cessation
- 2005-11-30 PT PT05852411T patent/PT1831237E/pt unknown
- 2005-11-30 AT AT05852411T patent/ATE405573T1/de active
- 2005-11-30 WO PCT/US2005/043125 patent/WO2006065525A1/en not_active Ceased
- 2005-11-30 DE DE602005009255T patent/DE602005009255D1/de not_active Expired - Lifetime
- 2005-11-30 CA CA2589850A patent/CA2589850C/en not_active Expired - Fee Related
- 2005-11-30 EA EA200701300A patent/EA011868B1/ru not_active IP Right Cessation
- 2005-11-30 RS RSP-2008/0502A patent/RS50629B/sr unknown
- 2005-11-30 PL PL05852411T patent/PL1831237T3/pl unknown
- 2005-11-30 NZ NZ554732A patent/NZ554732A/en not_active IP Right Cessation
- 2005-11-30 KR KR1020077013628A patent/KR100874052B1/ko not_active Expired - Fee Related
- 2005-11-30 MX MX2007007228A patent/MX2007007228A/es active IP Right Grant
- 2005-11-30 ES ES05852411T patent/ES2310860T3/es not_active Expired - Lifetime
- 2005-11-30 HR HR20080529T patent/HRP20080529T3/xx unknown
- 2005-11-30 EP EP05852411A patent/EP1831237B1/en not_active Expired - Lifetime
- 2005-11-30 AU AU2005316922A patent/AU2005316922B2/en not_active Ceased
- 2005-11-30 SI SI200530455T patent/SI1831237T1/sl unknown
- 2005-11-30 JP JP2007546709A patent/JP5022911B2/ja not_active Expired - Fee Related
- 2005-11-30 CN CN2005800431815A patent/CN101080417B/zh not_active Expired - Fee Related
- 2005-11-30 UA UAA200706706A patent/UA86119C2/ru unknown
- 2005-11-30 DK DK05852411T patent/DK1831237T3/da active
- 2005-12-15 AR ARP050105271A patent/AR055009A1/es unknown
- 2005-12-15 PE PE2005001474A patent/PE20060771A1/es not_active Application Discontinuation
- 2005-12-16 MY MYPI20055970A patent/MY143677A/en unknown
- 2005-12-19 TW TW094145118A patent/TWI326687B/zh not_active IP Right Cessation
-
2007
- 2007-06-04 ZA ZA200700501A patent/ZA200705019B/xx unknown
- 2007-06-04 IL IL183666A patent/IL183666A/en not_active IP Right Cessation
- 2007-06-29 NO NO20073368A patent/NO20073368L/no not_active Application Discontinuation
- 2007-07-13 MA MA30079A patent/MA29154B1/fr unknown
-
2008
- 2008-10-23 CY CY20081101194T patent/CY1108447T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008524218A5 (enExample) | ||
| RU2471782C2 (ru) | Твердые формы, содержащие (+)-2-[1-(3-этокси-4-метоксифенил)-2-метилсульфонилэтил]-4-ацетиламиноизоиндолин-1, 3-дион, их композиции и применение | |
| CN103945848B (zh) | 被取代的喹唑啉酮的口服即释制剂 | |
| NO20092033L (no) | Nye forbindelser | |
| JP2010514829A5 (enExample) | ||
| NO20083059L (no) | Pyrimidinderivater | |
| JP2014511892A5 (enExample) | ||
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| CL2008001898A1 (es) | Compuestos derivados de pirazinona, inhibidores de p38; proceso de preparacion de estos; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende; uso para tratar enferemedades pulmonares obstructivas cronicas y asma. | |
| JP2009535352A5 (enExample) | ||
| PA8534801A1 (es) | Derivados de piperazina | |
| TWI832361B (zh) | 具有高口服生物利用度的ｊａｋ抑制劑 | |
| JP2006509749A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| EA200971086A1 (ru) | Фармацевтические композиции и способ лечения шизофрении | |
| TW200918525A (en) | Compounds | |
| JP2014505107A5 (enExample) | ||
| BRPI0706863A2 (pt) | composição de fármacos, uso de uma composição de fármacos e embalagem comercial | |
| CA2589850A1 (en) | Amide prodrug of gemcitabine, compositions and use thereof | |
| CN100361975C (zh) | 5－羟基－3－羧酸酯吲哚类衍生物及其制备方法 | |
| JP2007500176A5 (enExample) | ||
| NO20071244L (no) | Anvendelse av cellespesifikke konjugater for behandling av inflammasjonssykdommer i gastrointestinaltrakten | |
| CN106008373B (zh) | 二取代双环衍生物及其作为外排泵抑制剂在抗菌中的应用 | |
| CN102596202A (zh) | 吡嘧司特新的晶形 | |
| JP2019516726A5 (enExample) |